Jonathan B. Siegel - May 18, 2022 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role
Director
Signature
/s/ Jonathan B. Siegel
Stock symbol
JAGX
Transactions as of
May 18, 2022
Transactions value $
$0
Form type
4
Date filed
5/18/2022, 04:33 PM
Previous filing
Mar 30, 2022
Next filing
May 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAGX Common Stock Options Exercise +12.1K 12.1K May 18, 2022 Direct F1, F2
holding JAGX Common Stock 4.43K May 18, 2022 See Footnote F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Restricted stock units Options Exercise $0 -12.1K -100% $0.00* 0 May 18, 2022 Common Stock 12.1K Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.
F3 Securities held directly by JBS Healthcare Ventures LLC. Mr. Siegel, by virtue of his position as the sole member of JBS Healthcare Ventures LLC, may be deemed to beneficially own the securities held by JBS Healthcare Ventures LLC for purposes of Section 16.
F4 The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date.